Identification of Novel Genetic Markers of Breast Cancer SurvivalQi Guo, Carmel Apicella, Constance Chen et al.|JNCI Journal of the National Cancer Institute|2015Cited by 244
Administration of continuous/intermittent olaparib in ovarian cancer patients with a germline BRCA1/2 mutation to determine an optimal dosing schedule for the tablet formulationJoaquı́n Mateo, L Rhoda Molife, Michael Friedländer et al.|Unknown|2013Cited by 19